Markets

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

By CNBC Mar 27, 2026 1 min read 7 views

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Markets

10 Nifty500 stocks with up to 60% upside potential; do you own any?

Several Nifty500 stocks may deliver strong returns over the next year, with analyst estimates indica...

Explained: Why RBI’s FCNR(B) and ECB swap window could be a game changer for banks

RBI’s FCNR(B) and ECB swap windows aim to boost liquidity, stabilise the rupee and ease funding co...

Vedanta demerger & HFCL dip: Anand James reveals how to trade this week's top stock triggers

Also, 23700 is a stiff barrier that had troubled May for several days, and is expected to pose a sti...

CEA Anantha Nageswaran says AI stock valuations definitely in a bubble

India's Chief Economic Advisor V Anantha Nageswaran warns that artificial intelligence stock valuati...

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

Related Articles

10 Nifty500 stocks with up to 60% upside potential; do you own any?

Explained: Why RBI’s FCNR(B) and ECB swap window could be a game changer for banks

Vedanta demerger &amp; HFCL dip: Anand James reveals how to trade this week's top stock triggers

CEA Anantha Nageswaran says AI stock valuations definitely in a bubble

Vedanta demerger & HFCL dip: Anand James reveals how to trade this week's top stock triggers